KORU Medical prelim Q4 revenue $10.9M (+23% YoY); FY revenue $41.1M (+22% YoY); positive op cash flow

KORU Medical Systems, Inc.

2025-FY EPS reported -$0.06 revenue$41,127,366

Preliminary Q4 2025 net revenue $10.9M, up 23% YoY; full year net revenue $41.1M, up 22% YoY.
Ending cash balance $8.9M; positive cash flow from operations in Q4 and for full year.
Submitted 510(k) for Freedom Infusion System for use with Phesgo, expanding into oncology.
Company plans to release final 2025 results and 2026 guidance in early March 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.